胰激肽原酶联合地尔硫卓治疗冠状动脉慢血流的疗效观察及对血管内皮功能的影响  

Efficacy of kallidinogenase combined with Diltiazem in the treatment of coronary artery slow blood flow and its effect on vascular endothelial function

作　　者：于萍[1] 郑磊[2] YU Ping;ZHENG Lei(Department of Cardiology,Beijing Hepingli Hospital,Beijing 100013,China)

机构地区：[1]北京市和平里医院心内科,北京市100013 [2]阜外心血管病医院心内科

出　　处：《中国心血管病研究》2018年第7期647-650,共4页Chinese Journal of Cardiovascular Research

摘　　要：目的 探讨胰激肽原酶联合地尔硫卓治疗冠状动脉慢血流（CSF）的效果及对血管内皮功能的影响.方法 经冠状动脉造影（CAG）确诊为CSF患者80例,随机分为治疗组和对照组.对照组给予盐酸地尔硫卓片,一次30 mg,每日3次;治疗组在对照组基础上服用胰激肽原酶肠溶片,一次120U,每日3次,疗程4周.观察两组治疗前后校正的血流分级计数（CTFC）及下降程度的变化,CSF临床症状改善效果,血清内皮素1 （ET-1）、超敏C蛋白（hs-CRP）和一氧化氮（NO）水平变化.结果 对照组和治疗组治疗前TIMI血流计数分别为（36.53±9.21比35.35±8.71）,比较未见统计学差异;治疗后对照组和治疗组TIMI分别为（23.47±7.75比21.59±7.58）,均显著降低（P＜0.05）,但组间比较未见统计学差异（P＞0.05）;治疗组有效32例（80.0％）,对照组有效22例（55.0％）,两组间有效率比较差异有统计学意义（P＜0.05）;治疗前对照组和治疗组ET-1和hs-CRP分别为[（22.45±3.68）pg/ml比（21.67±3.47）pg/ml,（4.25±1.41）mg/L比（4.16±2.02）mg/L],治疗后对照组和治疗组ET-1和hs-CRP分别为[（19.33±5.14）pg/ml比（14.33±4.29）pg/ml,（1.97±0.78）mg/L比（1.57±0.64）mg/L],与治疗前比较治疗后两组的ET-1和hs-CRP水平均出现显著下降（P＜0.05）,且治疗组改善效果更明显,与对照组比较差异有统计学意义（P＜0.05）.结论 胰激肽原酶联合地尔硫卓,可显著改善CSF患者临床症状,降低CTFC,改善血管内皮功能.Objective To explore the effect of kallidinogenase combined with Diltiazem on in the treatment of coronary flow （CSF）. Methods 80 patients with CSF were diagnosed by coronary angiography （CAG） were randomly divided into treatment group and control group. The control group was treated with Diltiazem hydrochloride tablets, 30 mg each time, three times a day; the treatment group treat with Diltiazem plus pancreatic kininase entericoated tablets, 120 U each time, three times a day, the treatment last for 4 weeks. Correct TIMI frame count （ CTFC ） and the degree of descent were observed before and after treatment, level of endothelin- 1 （ ET- 1 ）, high-sensitivity C protein （hs-CRP） and nitric oxide （NO） were evaluated and the improvement of clinical symptoms of CSF were observed. Results The blood flow counts of TIMI in the control group and the treatment group were （36.53±9.21 vs. 35.35±8.71）, respectively, and no statistical difference was found in the control group and the treatment group （23.47±7.75 vs. 21.59±7.58）, respectively （P〈0.05）, but there was no statistical difference between the groups （P〉0.05）, and the treatment group was 32 cases （80%）. In the control group, 22 cases （55%） were effective, and the difference between the two groups was statistically significant （P〈0.05）. The ET- 1 and hs-CRP in the control group and the treatment group were [ （22.45±3.68） pg/ml vs. （ 21.67±3.47 ） pg/ml, （4.25±1.41）mg/L vs. （4.16±2.02）mg/L]respectively, and ET-I and hs-CRP in the treatment group and the treatment group were [ （ 19.33±5.14）pg/ml vs. （ 14.33±4.29）pg/ml, （ 1.97±0.78）mg/L vs. （ 1.57±0.64）mg/L], the ET-I and hs-CRP levels in the two groups were significantly decreased （P〈0.05） after the treatment before treatment （P〈0.05）, and the improvement effect of the treatment group was more obvious, compared with the control group, the difference was statistically significant（P〈0.05 ）. Conclusion Pan

关 键 词：冠状动脉慢血流 胰激肽原酶 地尔硫卓 血管内皮功能 

分 类 号：R543.3[医药卫生—心血管疾病]